PIRAMAL PHARMA share price has zoomed 4% and is presently trading at Rs 225.8.
Meanwhile, the BSE HEALTHCARE index is at 42,818.4 (up 0.3%).
Among the top gainers in the BSE HEALTHCARE index today are ASTER DM HEALTHCARE (up 12.1%) and SYNGENE INTERNATIONAL (up 3.5%).
DR. LAL PATHLABS (down 2.5%) and Pfizer (down 1.5%) are among the top losers today.
Over the last one year, PIRAMAL PHARMA has moved up from Rs 93.8 to Rs 225.8, registering a gain of Rs 132.0 (up 140.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,503.7 to 42,818.4, registering a gain of 55.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 213.8%), Glenmark Pharma (up 121.2%) and SUVEN PHARMACEUTICALS (up 119.1%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 79,927.4 (down 0.2%).
The top losers among the BSE Sensex today are Hindustan Unilever (down 5.1%) and Nestle (down 1.5%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,362.2 (down 0.3%). Hindustan Unilever and Hindalco are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,571.9 to 79,927.4, registering a gain of 15,355.5 points (up 23.8%).
PIRAMAL PHARMA net profit grew 137.8% YoY to Rs 53 million for the quarter ended September 2024, compared to a loss of Rs 141 million a year ago. Net sales rose 17.3% to Rs 22,418 million during the period as against Rs 19,114 million in July-September 2023.
For the year ended March 2024, PIRAMAL PHARMA reported 109.6% increase in net profit to Rs 178 million compared to net loss of Rs 1,865 million during FY23. Revenue of the company grew 15.4% to Rs 81,712 million during FY24.
The current Price to earnings ratio of PIRAMAL PHARMA, based on rolling 12 month earnings, stands at -1473.9.
Equitymaster requests your view! Post a comment on "PIRAMAL PHARMA Gains 4%; BSE HEALTHCARE Index Up 0.3%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!